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Abstract
Purpose In-vivo quantification of tumor uptake of 89-zirconium (89Zr)-labelled monoclonal antibodies (mAbs) with PET pro-
vides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for 89Zr-immuno-
PET is low tumor contrast. This is expected to result in interobserver variation in tumor delineation. Therefore, the aim of this
study was to determine interobserver reproducibility of tumor uptake measures by tumor delineation on 89Zr-immuno-PETscans.
Methods Data were obtained from previously published clinical studies performed with 89Zr-rituximab, 89Zr-cetuximab and
89Zr-trastuzumab. Tumor lesions on 89Zr-immuno-PETwere identified as focal uptake exceeding local background by a nuclear
medicine physician. Three observers independently manually delineated volumes of interest (VOI). Maximum, peak and mean
standardized uptake values (SUVmax, SUVpeak and SUVmean) were used to quantify tumor uptake. Interobserver variability was
expressed as the coefficient of variation (CoV). The performance of semi-automatic VOI delineation using 50% of background-
corrected ACpeak was described.
Results In total, 103 VOI were delineated (3–6 days post injection (D3-D6)). Tumor uptake (median, interquartile range) was 9.2
(5.2–12.6), 6.9 (4.0–9.6) and 5.5 (3.3–7.8) for SUVmax, SUVpeak and SUVmean. Interobserver variability was 0% (0–12), 0% (0–
2) and 7% (5–14), respectively (n = 103). The success rate of the semi-automatic method was 45%. Inclusion of background was
the main reason for failure of semi-automatic VOI.
Conclusions This study shows that interobserver reproducibility of tumor uptake quantification on 89Zr-immuno-PET was
excellent for SUVmax and SUVpeak using a standardized manual procedure for tumor segmentation. Semi-automatic delineation
was not robust due to limited tumor contrast.
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Introduction
Therapy with monoclonal antibodies (mAbs) has greatly
improved the outcome of cancer patients [1]. However,
treatment failure due to the biology of the disease is a
substantial problem. In addition to disease-related factors,
therapy-related factors have been found to be responsible
[2]. There is mainly information on pharmacokinetics in
blood, whereas tumor targeting is crucial for mAb effica-
cy. Therefore, in-vivo quantification of antibody uptake in
tumors is of interest in strategies to improve the efficacy
of antibody treatment (e.g. using optimized pharmacoki-
netic models in early drug development to improve dosing
schedules). PET imaging with zirconium-89 (89Zr)-la-
belled mAbs provides a non-invasive tool to visualize
and quantify mAb tumor uptake [3], providing that
biodistribution of the radiolabelled mAb represents that
of the total mAb dose (radiolabelled and unlabelled).
The number of clinical studies on 89Zr-labelled mAbs,
also referred to as 89Zr-immuno-PET, increased in recent
years [4]. Sources of measurement errors (including fac-
tors such as interobserver reproducibility of tumor uptake
quantification and noise induced variability) should be
known to define true biological differences. A standard-
ized method of data acquisition and tumor uptake quanti-
fication forms the basis for obtaining experimental data
that will allow such an understanding.
For quantification of tumor uptake, a volume of interest
(VOI) is delineated. Subsequently, a tumor uptake measure
is selected to characterize tumor uptake. Maximum (max) or
peak standard uptake values (SUVmax and SUVpeak, respec-
tively) provide information on a limited part of the tumor.
Mean standardized uptake values (SUVmean) and total lesion
uptake (TLU) serve to capture the entire lesion. In clinical
studies, tumor uptake is quantified at a single (late) timepoint
or at multiple timepoints. Additionally, quantification of tu-
mor uptake at an early timepoint (D0) can be considered, for
example, to estimate the blood volume fraction of the tumor.
For imaging of mAbs, 89Zr is considered a suitable radio-
active isotope due to its long half-life (t1/2 = 78.4 h), which
matches the slow kinetics of large-sized proteins.
Consequences of imaging with 89Zr are low positron abun-
dance and relatively high radiation exposure, resulting in low-
er injected doses compared to 18F. Therefore, lower signal to
noise ratios due to lower count rates may result in interobserv-
er variability of tumor uptake quantification in 89Zr-immuno-
PET. Other specific challenges for 89Zr-immuno-PET tumor
delineation and quantification are relatively low, sometimes
heterogeneous, tumor uptake (Fig. 1) and low (or even nega-
tive) contrast depending on tumor localization and back-
ground activity [5]. Therefore, the aim of this study was to
determine interobserver reproducibility of tumor uptake
values by manual delineation on 89Zr-immuno-PET.
Materials and methods
Data inclusion
For this retrospective study, 89Zr-immuno-PET scans with corre-
sponding 18F-FDG-PETscanswere collected.Datawere selected
from previously published clinical studies with therapeutic
mAbs: 89Zr-rituximab in patients with B cell lymphoma ([6];
Dutch Trial Register NTR 3392), 89Zr-cetuximab in patients with
colorectal cancer ([5]; NCT01691391) and 89Zr-trastuzumab in
patients with breast cancer ([7]; NCT01691391). These studies
had been approved by the ethics committees (Medisch Ethische
Toetsingscommissie VUmc and Medisch Ethische
Toetsingscommissie UMC Groningen) and all subjects signed
an informed consent. Data acquisition and visual assessment of
tumor uptake was done locally: from the first two studies per-
formed at the VUmc all subjects with visible tumor uptake were
included, from the last study performed at the UMCG seven
subjects were selected randomly. Scan data at 1 h (D0), 72 h
(D3) and 144 h (D6) post injection (p.i.) for 89Zr- labelled ritux-
imab and cetuximab and at 96 h (D4) p.i. for 89Zr-trastuzumab
were included. See Table 1 for patient characteristics and 89Zr-
immuno-PET scan details. 89Zr-rituximab and 89Zr-cetuximab
PET scans were performed on a Philips Gemini TF-64 or
Ingenuity TF-128 PET-CT scanner (Philips Healthcare,
TheNetherlands). A Siemens BiographmCT64 PET-CTscanner
(Siemens Healthcare, The Netherlands) was used for the 89Zr-
trastuzumab-PET scans.
VOI delineation
All immuno-PET scans were acquired and reconstructed to con-
form to recommendations for multicenter harmonization of 89Zr-
immuno-PET [8]. Visual assessment of immuno-PET scans was
performed by an experienced nuclear medicine physician (OSH
for 89Zr-rituximab and 89Zr-cetuximab, AHB for 89Zr-
trastuzumab). Tumor uptake was defined as focal uptake exceed-
ing local background. For visually positive tumor lesions, a
screenshot indicating tumor localization on immuno-PET was
obtained for tumor uptake quantification. Quantitative assess-
ment of tumor uptake for all lesions was independently per-
formed by three observers [1 data analyst (SP), 2 physician-
researchers (FB, YJ)]. Tumor delineation for all VOI was per-
formed using the ACCURATE software tool (developed in IDL
version 8.4 (Harris Geospatial Solutions, Bloomfield, USA)) [9].
The observers recorded the analysis time per tumor lesion
and VOI delineation method.
Manual tumor delineation on immuno-PET The observers
manually delineated tumor VOI on the immuno-PET scans
(attenuation corrected image), using the low dose CT for an-
atomical reference (Fig. 2a). Adjustment of the following set-
tings was allowed: zoom, contrast and orientation (coronal/
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Fig. 1 Challenges for 89Zr-
immuno-PET tumor delineation
and quantification. Example of
18F-FDG-PET (a) for a patient
with a non-Hodgkin lymphoma
showing intense tumor uptake
(black arrow) and excellent con-
trast, while 89Zr-immuno-PET (b)
with 89Zr-labelled-rituximab
shows limited contrast for this tu-
mor. Red arrows indicate uptake
in blood vessels. Example of tu-
mor delineation by two observers
(observer 1 = blue line, observer
2 = black line) for 18F-FDG-PET
(c) and 89Zr-immuno-PET (d).
This example illustrates that ex-
cellent interobserver reproduc-
ibility (SUVmax = 10 for both ob-
servers) can be expected for 18F-
FDG-PET, despite variability in
tumor delineation. The limited
tumor contrast for 89Zr-immuno-
PET may result in substantial in-
terobserver variability, even for
SUVmax (a value of 2 and 3 for
observers 1 and 2, respectively)
Table 1 Patient characteristics
and 89Zr-immuno-PET scan
details
Patient mAb Gender Injected dose (MBq) 89Zr-immuno-PET (n = number of VOI)
D0 D3 D4 D6
1 Rituximab F 69.8 1 1 – 1
2 Rituximab M 75.3 22 22 – 22
3 Rituximab M 79.2 2 2 – 2
4 Rituximab M 75.0 0a 1 – 1
5 Rituximab F 75.6 6 0 – 6
6 Cetuximab F 36.7 2 2 – 2
7 Cetuximab M 35.6 2 2 – 2
8 Cetuximab F 36.2 2 2 – 2
9 Cetuximab F 36.5 1 1 – 1
10 Cetuximab F 35.5 2 0 – 2
11 Cetuximab M 38.1 0b 0 – 1
12 Trastuzumab F 35.0 – – 5 –
13 Trastuzumab F 38.2 – – 4 –
14 Trastuzumab F 35.8 – – 5 –
15 Trastuzumab F 37.3 – – 4 –
16 Trastuzumab F 38.3 – – 5 –
17 Trastuzumab F 35.3 – – 2 –
18 Trastuzumab F 37.0 – – 3 –
Total 40 103
a Technical error: 1 VOI missing for patient 4
bNo D0 scan available: 1 VOI missing for patient 11
D0 VOI were delineated on D6 and imported to the D0 scan (data marked in italics)
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axial/sagittal). Use of a threshold (upper or lower limit) or
fixed size VOI was not allowed. For 89Zr-rituximab and
89Zr-cetuximab, tumors were manually delineated on both
the D3 and D6 scans, starting with the latest time point. On
D0, no tumor uptake was visible, therefore the VOI delineated
on D6 were imported to the D0 scan. Observers could manu-
ally adjust localization of the VOI to optimize matching of the
anatomical position of the tumor lesion on the D0 scan.
For all VOI, max, peak and mean activity concentrations
(AC in Bq/mL) were derived and converted to standardized
uptake values (SUV), by correcting for body weight and
injected dose (ID). In addition, delineated volume (mL) and
TLU (defined as ACmean * volume, in %ID) were obtained.
Manual tumor delineation on immuno-PET after viewing the 18F-
FDG-PET In order to support delineation of the tumor, the ob-
servers had access to the corresponding 18F-FDG-PET and
could adapt the original manually delineated VOI if necessary
(for example, by creating a smaller or larger VOI, or changing
the position of the VOI) (Fig. 2b). This procedure was per-
formed on scans with visible tumor uptake (D3, D4, D6). The
number of VOIs that were adapted after viewing the 18F-FDG-
PETwas obtained.
Semi-automatic VOI delineation Finally, we investigated the
feasibility of a mask-restricted semi-automatic VOI delinea-
tion method. Each observer, for every tumor lesion, manually
delineated a mask, which is a VOI including the tumor, ex-
cluding non-tumor structures (e.g. nearby blood vessels) on
the immuno-PETscan. Subsequently, the semi-automatic VOI
was generated including all voxels with a value ≥50% of
background-corrected ACpeak within the mask (Fig. 2c). The
semi-automatic isocontour was defined as 0.5 * (peak value +
average background value). The background region was
Fig. 2 VOI delineation methods for 89Zr-immuno-PET. Manual tumor
delineation on immuno-PET (a) using the low dose CT (left panel), at-
tenuation corrected 89Zr-cetuximab-PET on D6 (middle panel) with tu-
mor lesion indicated by the red arrow and example VOI on 89Zr-
cetuximab-PET shown in green (right panel). Manual tumor delineation
on immuno-PETafter reviewing the corresponding 18F-FDG-PET (b) the
original manually delineated VOI shown in green on the 89Zr-
trastuzumab-PET on D4 (left panel), reviewing the 18F-FDG-PET scan
with tumor lesion indicated by the red arrow (middle panel) and adapting
the original VOI after reviewing the 18F-FDG-PET scan; the FDG
adapted tumor VOI shown on 89Zr-trastuzumab-PET is in green (right
panel). Semi-automatic delineation (c) with the attenuation corrected
89Zr-rituximab-PET on D6 (left panel), the mask delineated on the 89Zr-
rituximab-PET shown in orange (middle panel) and the semi-automatic
VOI (50% of ACpeak, mask restricted) on the
89Zr-rituximab-PET shown
in green (right panel). This semi-automatic VOI was accepted by the
observer, as it contains tumor and no other structures or background
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determined with a region growing algorithm of the tumor
border, expanding three voxels away from the border of the
tumor in all three dimensions [10]. The observers rated the
semi-automatic VOI and accepted the VOI if it contained the
tumor and no other structures or background. The number of
tumor lesions for which the semi-automatic VOI was accepted
by all observers was obtained.
Eligibility criteria for VOI delineation
Quantification of lesions with low tumor uptake and/or high
background uptake (e.g. lesions with low contrast and/or nearby
presence of blood vessels or elevated healthy tissue uptake) is
difficult, due to the intrinsically low signal to noise ratios in 89Zr-
immuno-PET. To ensure that quantification is only reported
when delineation is feasible, a method to determine eligibility
for VOI delineation was explored. Criteria were selected based
on the potential for incorporation in a standardized workflow for
tumor identification by a nuclear medicine physician, followed
by tumor delineation by a data-analyst.
When measurement variability for SUVmax was >0, VOI
were assessed for apparent insufficient tumor contrast for
manual tumor delineation.
Based on this assessment VOI were deemed ineligible for
quantification, according to the following criteria:
1. A different structure was delineated by at least one
observer.
2. The voxel with maximum intensity was located at the
border of the VOI, of at least one observer.
Interobserver variability and reliability were analyzed for
the entire group of VOI, as well as for the subset of VOI
eligible for quantification.
Interobserver reproducibility
Interobserver reproducibility for manual tumor delineation on
immuno-PETwas assessed by an agreement parameter (standard
error of measurement (SEM)) as well as a reliability parameter
(ICC; [11]). As we expected that the interobserver variability
between lesions within a single patient was equal or higher than
between patients, we performed a VOI-based analysis.
Interobserver variability The agreement parameter reflects the
measurement error due to interobserver variability [11]. For
every tumor lesion, three values (value1, value2 and value3)
were obtained from observers 1, 2 and 3, respectively.
Absolute interobserver variability was calculated as:
SEM ¼ SD value1; value2; value3ð Þ; ð1Þ
where SD is the standard deviation.
SEM was calculated for each individual tumor lesion and
has the same unit as the uptake measure (SUVmax, SUVpeak
and SUVmean, dimensionless; volume in mL; TLU in %ID).
Relative interobserver variability was calculated as:
CoV ¼ SEM=average value 1; value 2; value 3ð Þ*100; ð2Þ
where CoV (%) is the coefficient of variation.
When all observers measure the exact same tumor uptake,
SEM and CoVequal 0.
Correlation of absolute and relative variability with tumor
uptake was assessed. For a group of n VOI, the interobserver
variability is given as the median (interquartile range).
Reliability A reliability parameter was used to assess whether
differences in tumor uptake between lesions can be distin-
guished, despite measurement error due to interobserver var-
iability. A two-way random model with absolute agreement
(single measure) was used to obtain the ICC and 95% confi-
dence interval. This means that the three observers in our
study were considered as a random sample of all possible
observers, and the systematic differences between the ob-
servers were included in the measurement error as we were
interested in absolute agreement between the observers.
Reliability, expressed as ICC, was calculated as:
ICC ¼ σ2lesion= σ2lesion þ σ2obs þ σ2error
 
; ð3Þ
where σ2obs is the systematic part, and σ
2
error is the random
part of the measurement error, while σ2 lesion is the true vari-
ance between tumor lesions. ICC calculations were performed
in SPSS, version 22.
Statistical analysis
For comparison of interobserver variability between two groups,
Wilcoxon matched-pairs signed rank test was used for paired
data (e.g. SUVmean on D3 and D6 for the same tumor lesions).
For comparison of median CoV between multiple groups, a one-
way ANOVA (non-parametric) was performed, using Friedman
test with Dunn’s multiple correction to compare median CoV for
paired data (SUVmean, SUVmax and SUVpeak for the same tumor
lesions). For all statistical tests, a p value <0.05 was considered
statistically significant. Statistical tests were performed in
GraphPad Prism, version 6.02.
Results
VOI delineation
In total, 103 VOI were manually delineated by each observer.
The number of VOI was not evenly distributed over the
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patients (Table 1). The range in interobserver variability (SEM
for SUVpeak) for all VOI combined was 0 to 2.3 (median 0.4,
n = 103). The range in interobserver variability between VOI
within a single patient was 0 to 2.3 (median 0.6, n = 22) for
patient 2 (89Zr-rituximab at D6). Interobserver variability
(SEM) at D6 for the remaining five 89Zr-rituximab patients
ranged from 0.1 to 1.4 (median 0.3, n = 8).
Thus, as interobserver variability was higher within a single
patient than between patients, a VOI-based analysis was
performed.
Manual delineation on 89Zr-immuno-PET required a medi-
an time of 2 min (range 1–5 min). Viewing of the 18F-FDG-
PET /adaption of the original VOI required an additional time
of 1 min (range 1–30 min). The semi-automatic procedure
required 1 min (range 1–5 min).
All observers reported difficulties to distinguish the borders
of some tumor lesions on immuno-PET, especially if the tu-
mor was in proximity to other structures with high uptake, e.g.
a blood vessel. Viewing the corresponding 18F-FDG-PET did
not resolve this issue, as the localization and borders of the
tumor lesions on immuno-PETwere still not fully clear when
viewing both the immuno-PET and the 18F-FDG-PET. After
viewing the corresponding 18F-FDG-PET, 25% of the VOI
were adapted by at least one observer (Table 2).
Semi-automatically generated VOI were accepted by all three
observers in 45% of all VOI (Table 2). Inclusion of background
was the main reason for failure of semi-automatic VOI.
Eligibility criteria for VOI delineation
Measurement variability for SUVmax was >0 in 25% (26/103)
of the manually delineated VOI.
In 4% of the cases (4/103) a different structure (e.g. another
tumor lesion) was delineated by at least one observer (2/32
(D6) for 89Zr-rituximab; 1/10 (D6) for 89Zr-cetuximab and 1/
28 (D4) for 89Zr-trastuzumab). In 15% of the cases (15/103),
the voxel with the maximum intensity was located at the bor-
der of the VOI (3/26 (D3) and 2/30 (D6) for 89Zr-rituximab; 5/
7 (D3) and 1/9 (D6) for 89Zr-cetuximab and 4/27 (D4) for
89Zr-trastuzumab).
Application of eligibility criteria resulted in exclusion of 19




Relative interobserver variability (CoV) was not correlated with
tumor uptake (SUVmean) (Fig. 3). Therefore, interobserver variabil-
ity is reported as a relative value per individual VOI and per
datagroup (e.g. timepoint, mAb) (Table 3). For all VOI combined
(n= 103), interobserver variability was 0% (0–2) for SUVmax, 0%
(0–12) for SUVpeak and 7% (5–14) for SUVmean. Manual delinea-
tion resulted in an interobserver variability of 35% (21–49) for
delineated volume and 30% (17–44) for TLU.
There was no difference in interobserver variability for VOI
delineated at D3 or D6 for 89Zr-rituximab (6 vs 8%, p= 0.38,
n = 26). To obtain tumor uptake at D0 (without visible tumor
contrast), a different technique was applied (importing VOI delin-
eated at D6 to the D0 scan). Using this method, interobserver
variability for SUVmean at D0 was 13% (8–28) for
89Zr-rituximab
and 10% (5–27) for 89Zr-cetuximab (Supplemental Table 1).
Interobserver variability did not change after viewing the
corresponding 18F-FDG-PET (p = 0.62, n = 25 VOI adapted
by at least 1 observer).
VOI eligible for quantification (n= 84) showed higher tumor
uptake (median SUVpeak of 7.6 vs 3.8, p<0.001) and lower inter-
observer variability (SUVpeak, 0 vs 17%, p< 0.001) compared to
ineligible VOI (n= 19).
Reliability ICC data are presented in Table 4. For eligible VOI,
ICC values for SUVmax, SUVpeak and SUVmean were≥ 0.90 for
89Zr-rituximab (D3, D6) and 89Zr-cetuximab (D6). For 89Zr-
trastuzumab, ICC values ≥ 0.82 were obtained. For volume and
TLU ICCvalueswere > 0.66 for allmAbs. In addition, ICCvalues
for all combinations of two observers were calculated
(Supplemental Table 2).
Discussion
Interobserver reproducibility for tumor uptake measures was
investigated, as knowledge of measurement error is required
for future clinical application of 89Zr-immuno-PET.
Interobserver reproducibility was excellent for SUVmax and
SUVpeak (variability of 0%) and very reasonable for
Table 2 Effect of viewing the
18F-FDG-PET on manual tumor
delineation on immuno-PET and









D3 D6 D3 D6 D4
% of VOI changed by ≥1 observer after viewing the
18F-FDG-PET
19% 34% 0% 10% 31%a 25%
% of VOI accepted after semi-automatic delineation 58% 66% 14% 30% 21% 45%
aNo 18 F-FDG-PET available for patient 17
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SUVmean (variability of 7%), especially considering the lower
signal to noise ratios for 89Zr-immuno-PET compared to 18F-
FDG-PET. For example, interobserver variability of 14% for
SUVmean has been reported for manual tumor delineation of
pulmonary lesions on 18F-FDG-PET [12].
For 89Zr-immuno-PET, this is the first study to report
interobserver reproducibility of tumor uptake measures.
Several factors should be considered to determine to which
extent these results are generalizable. Interobserver repro-
ducibility was determined for three different 89Zr-labelled
mAbs (rituximab, cetuximab and trastuzumab), at different
time points (D3, D4, D6) and different injected doses
(74 MBq for 89Zr-rituximab vs 37 MBq for 89Zr-
trastuzumab and 89Zr-cetuximab). This study was not de-
signed to assess how these factors individually impact in-
terobserver variability. Instead, the results obtained reflect
a broad range of uptake characteristics, which can be used
as a general estimate of the measurement error due to in-
terobserver variability in VOI delineation. Future, larger
studies can focus on factors that influence tumor contrast
(e.g. tumor localization, differences in uptake characteris-
tics between mAbs).
Fig. 3 Absolute and relative interobserver variability as a function of
tumor uptake. a Absolute variability (SEM) per individual VOI as a
function of tumor uptake (SUVmean), Spearman correlation coefficient
is 0.47 and p < 0.0001 (n = 103). b Relative variability (CoV) per
individual VOI as a function of tumor uptake (SUVmean). Spearman cor-
relation coefficient is −0.16 and p = 0.10 (n = 103). SUVmean is presented
as the average value for observers 1, 2 and 3
Table 3 Interobserver variability for 89Zr-immuno-PET
Measure 89Zr-rituximab 89Zr-cetuximab 89Zr-trastuzumab All VOI combined
D3 D6 D3 D6 D4
SUVmax All 0 (0–5); n = 26
8.0 (5.3–11.5)
0 (0–1); n = 32
11.8 (5.3–17.3)
0 (0–0); n = 7
10.2 (9.3–13.0)
0 (0–5); n = 10
5.4 (3.7–8.8)
0 (0–7); n = 28
8.6 (5.6–12.1)
0 (0–2); n = 103
9.2 (5.2–12.6)
Eligible 0 (0–5); n = 23
8.4 (5.3–11.4)
0 (0–0); n = 28
12.4 (6.1–18.0)
0 (0–0); n = 2
14.2(13.0–15.4)
0 (0–0); n = 8
4.1 (3.6–8.3)
0 (0–0); n = 23
9.9 (5.9–12.6)
0 (0–0); n = 84
9.8 (5.5–13.5)
SUVpeak All 0 (0–0); n = 26
8.7 (5.9–10.0)
0 (0–3); n = 32
8.5 (4.3–14.1)
0 (12–17); n = 7
4.2 (1.8–5.8)
0 (0–6); n = 10
4.4 (3.0–7.3)
18 (0–32); n = 28
5.6 (3.7–8.2)
0 (0–12); n = 103
6.9 (4.0–9.6)
Eligible 0 (0–0); n = 23
8.9 (7.3–10.1)
0 (0–0); n = 28
9.7 (4.7–14.5)
0 (0–0); n = 2
5.7 (5.3–6.1)
0 (0–0); n = 8
3.2 (2.9–6.8)
0 (0–30); n = 23
6.3 (4.0–8.8)
0 (0–0); n = 84
7.6 (4.7–10.4)
SUVmean All 6 (5–12); n = 26
6.8 (5.0–7.7)
7 (4–14); n = 32
7.0 (3.9–9.1)
12 (7–15); n = 7
3.3 (1.6–4.8)
10 (5–15); n = 10
3.8 (2.7–4.8)
7 (5–15); n = 28
5.0 (3.1–7.9)
7 (5–14); n = 103
5.5 (3.3–7.8)
Eligible 6 (5–12); n = 23
6.9 (6.1–7.3)
7 (4–12); n = 28
7.8 (4.2–9.2)
6 (3–8); n = 2
4.7 (4.2–5.1)
8 (4–10); n = 8
3.1 (2.6–4.6)
7 (5–13); n = 23
5.1 (3.9–8.0)
7 (5–11); n = 84
6.5 (4.1–8.0)
Volume (mL) All 26(19–47); n = 26
7.8 (4.2–25.0)
41(18–59); n = 32
7.7 (3.9–17.6)
35 (29–47); n = 7
3.6 (2.3–7.4)
39 (29–66); n = 10
4.1 (2.2–44.8)
36 (25–77); n = 28
4.9 (2.1–8.7)
35 (21–49); n = 103
6.1 (3.6–14.8)
Eligible 23(19–35); n = 23
8.8 (3.8–25.6)
36(17–49); n = 28
7.7 (3.8–16.5)
42(35–48); n = 2
85.1(2.3–167.9)
35 (22–46); n = 8
3.2 (2.1–106)
35 (24–48); n = 23
5.1 (2.4–10.8)
33 (19–46); n = 84
6.5 (3.5–16.5)
TLU (%ID) All 21(15–34); n = 26
0.06(0.03–0.13)
32(13–45); n = 32
0.05(0.02–0.17)
38 (34–46); n = 7
0.02(0.01–0.03)
32 (21–56); n = 10
0.01(0.01–0.26)
27 (18–70); n = 28
0.05 (0.01–0.08)
30 (17–44); n = 103
0.05 (0.02–0.12)
Eligible 18(14–31); n = 23
0.07 (0.03–0.18)
27(12–42); n = 28
0.05 (0.02–0.15)
36(34–38); n = 2
0.43 (0.01–0.85)
30 (18–39); n = 8
0.01 (0.01–0.55)
26 (18–35); n = 23
0.06 (0.02–0.12)
25 (16–37); n = 84
0.06 (0.02–0.13)
Data is presented as interobserver variability (CoV in %) on the first line and VOI metric on the second line as median value (interquartile range)
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Although ICC are reported, reliability is dependent
on the range in tumor uptake and therefore not directly
generalizable to other studies. In addition, tumor uptake
and interobserver variability are influenced by the dis-
proportionate high number of lesions in patient 2.
Therefore, ICC values for this lesion-based analysis can-
not be applied to determine whether we can reliably
detect differences between patients.
Improved tumor contrast, in combination with a broad
range in tumor uptake, is expected to result in improved inter-
observer reproducibility for all tumor uptake measures.
Another aspect to consider is that all observers used the
same quantification software and a standardized operating
procedure (no use of thresholds or fixed size VOI). Use of
different software platforms without a standardized procedure
may result in lower interobserver reproducibility. In addition,
generalizability could be hampered if the three observers
would have read the images in a systematically different
way. In this study, there was no indication for such a system-
atic difference between the three observers.
These results suggest that interobserver agreement for
SUVmean is sufficient to consider this uptake measure to quan-
tify tumor uptake in a larger tumor area (opposed to only the
maximum voxel or very small sample of the tumor as defined
by SUVpeak). However, manual tumor delineation is a
laborious task. As the concept of total lesion mAb uptake is
of interest, the feasibility of semi-automatic VOI delineation
was explored. For 18F-FDG-PET with perfect interobserver
agreement for SUVmax [13] and higher tumor contrast, semi-
automatic procedures are used to obtain SUVmean based on a
semi-automatic method (e.g. with a threshold of 0.6 of
SUVmax), total lesion glycolysis (TLG) and total metabolic
tumor volume (TMTV) [14, 15]. For our datasets, the area
included by the semi-automatic VOI was often too large, in-
dicating low tumor to local background ratios, resulting in
inclusion of background voxels in the semi-automatic VOI.
For mAbs showing higher tumor contrast, as well as imaging
with higher count statistics (due to, for example, higher
injected doses or the availability of scanners with improved
detection sensitivity or time of flight resolution), semi-
automatic delineation may be feasible. Reduction of noise
(e.g. by introduction of total body PET scanners) is the first
step towards further improvement of tumor delineation proce-
dures. Future studies into accuracy of tumor delineation
should include ‘supervised’ delineation methods (semi-
automatic procedures with a manual check) in which the op-
timal threshold is experimentally determined. If the success
rate can thus be increased, this may lead to further develop-
ment towards a robust automatic method, which is desired for
clinical application.
Table 4 Reliability of tumor
uptake quantification for 89Zr-
immuno-PET
Measure 89Zr-rituximab 89Zr-cetuximab 89Zr-
trastuzumab
D3 D6 D3 D6 D4
SUVmax All 1.00; n = 26
(1.00–1.00)
1.00; n = 32
(1.00–1.00)
0.93; n = 7
(0.77–0.99)
0.72; n = 10
(0.41–0.91)
0.97; n = 28
(0.95–0.99)
Eligible 1.00; n = 23
(1.00–1.00)
1.00; n = 28
(1.00–1.00)
NAa 1.00; n = 8
(NA-NA)
0.97; n = 23
(0.95–0.99)
SUVpeak All 1.00; n = 26
(1.00–1.00)
1.00; n = 32
(1.00–1.00)
0.94; n = 7
(0.82–0.99)
0.75; n = 10
(0.46–0.92)
0.83; n = 28
(0.69–0.92)
Eligible 1.00; n = 23
(1.00–1.00)
1.00; n = 28
(1.00–1.00)
NAa 1.00; n = 8
(1.00–1.00)
0.82; n = 23
(0.64–0.91)
SUVmean All 0.92; n = 26
(0.84–0.96)
0.95; n = 32
(0.91–0.97)
0.93; n = 7
(0.79–0.99)
0.79; n = 10
(0.56–0.96)
0.94; n = 28
(0.89–0.97)
Eligible 0.90; n = 23
(0.80–0.96)
0.94; n = 28
(0.90–0.97)
NAa 0.92; n = 8
(0.73–0.98)
0.93; n = 23
(0.86–0.97)
Volume (mL) All 0.85; n = 26
(0.74–0.92)
0.12; n = 32
(−0.07–0.36)
0.80; n = 7
(0.46–0.96)
0.83; n = 10
(0.60–0.95)
0.67; n = 28
(0.48–0.82)
Eligible 0.87; n = 23
(0.77–0.94)
0.72; n = 28
(0.55–0.85)
NAa 0.83; n = 8
(0.56–0.96)
0.66; n = 23
(0.45–0.82)
TLU (%ID) All 0.90; n = 26
(0.83–0.95)
0.65; n = 32
(0.47–0.79)
0.86; n = 7
(0.61–0.97)
0.89; n = 10
(0.72–0.97)
0.71; n = 28
(0.54–0.84)
Eligible 0.90; n = 23
(0.82–0.96)
0.83; n = 28
(0.72–0.91)
NAa 0.89; n = 8
(0.70–0.98)
0.70; n = 23
(0.51–0.85)
Data presented as ICC (95% confidence interval)
aNA ICC not available, 2 eligible VOI
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As semi-automatic delineation was not feasible in our
datasets, we explored eligibility criteria to improve standard-
ization for manual tumor delineation, especially in case of
limited tumor contrast.
In our study, 81% of the VOI (84 out of 103) were consid-
ered suitable for quantification. Based on these results, we
recommend a two-step procedure to exclude lesions with in-
sufficient tumor contrast for manual delineation: (1) verifica-
tion of VOI delineation by a nuclear medicine physician to
identify delineation of an incorrect structure due to limited
tumor contrast, (2) exclusion of VOI with the voxel with the
highest uptake located at the border of the VOI, indicating low
tumor uptake and/or high background uptake.
These measures support optimal scan interpretation
and standardization, which is an essential step towards
potential clinical implementation of 89Zr-immuno-PET.
For this study, we performed a multicenter interobserver
analysis for data that was originally obtained in single center
studies. With this experience, the next step towards standard-
ization of quantification for 89Zr-immuno-PET studies can be
done in the context of a multicenter study [e.g. the IMPACT
trials, (NCT02228954, NCT02117466 and NCT01957332)].
Reliable delineation of tumor uptake on 89Zr-immuno-PET
allows future use as a non-invasive clinical tool to determine
mAb concentrations in the tumor. Knowledge on in-vivo drug
delivery of mAb-based therapy (including antibody-drug con-
jugates, bispecific mAbs and immune checkpoint inhibitors)
is crucial to understand and predict efficacy of treatment.
Conclusion
This study shows that interobserver reproducibility of tumor
uptake quantification on 89Zr-immuno-PET was excellent for
SUVmax and SUVpeak using a standardized manual procedure
for tumor segmentation. Semi-automatic delineation was not
robust due to limited tumor contrast.
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